Bendamustine/brentuximab vedotin
- PDF / 181,600 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 16 Downloads / 148 Views
1 S
Acute renal failure and Pneumocystis pneumonia: 2 case reports In a study of 9 patients, two patients [ages and sexes not stated] were described, who developed acute renal failure or Pneumocystis pneumonia during treatment with bendamustine and brentuximab vedotin for advanced-stage CD30 positive cutaneous T-cell lymphomas [routes, times to reactions onsets and outcomes not stated]. Both the patients received bendamustine 120 mg/m2 and brentuximab vedotin 1.8 mg/kg every 3 weeks. Subsequently, the patients developed severe acute renal failure (1 patient) or Pneumocystis pneumonia (1 patient). The patient with acute renal failure, had a single kidney. Dumont M, et al. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas. British Journal of Dermatology 181: 803444421 1315-1317, No. 6, Dec 2019. Available from: URL: http://doi.org/10.1111/bjd.18215
0114-9954/20/1786-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 11 Jan 2020 No. 1786
Data Loading...
